With all the time, effort, heated debates, and battles that have taken place to date on health care, the discussion has actually been limited to reforming our health care economics but has not been focused on a genuine reform of health care itself. Therefore, as the effort to revise the US health care system unfolds, it is imperative that we evaluate and implement integrative strategies that will yield genuine and substantial cost savings while having a favorable impact on patient care. Before going forward, it is essential to acknowledge that without broadening the existing medical model, we will continue to perpetuate our inadequate and costly health care system.
Integrative treatments have the potential to reduce health care costs in a remarkable number of ways-from providing effective approaches for prevention to relieving treatment consequences. For instance, integrative lifestyle counseling may reduce the need for certain prescriptive medications, shrinking not only the initial costs for these drugs but ultimately the number of adverse drug reactions. With hospitalizations for adverse reactions to prescription medications running to 1.6 million annually and deaths amounting to more than 100 000 per year, such reactions are definitely contributing to runaway health care costs. So too is the lack of educating and training Americans in new health care behaviors. Over the past few decades, we Americans have become a sick society. The scourges of obesity, diabetes, and cancer continue to escalate with almost no success at prevention and only limited success with treatment. When it comes to cancer, the publicized survival breakthroughs are measured in a few weeks to a few months. The need to fix our system is beyond desperate in light of the financial and clinical health crises we find our country in. A disease prevention model should be core to any reform. Introducing a variety of preventative measures is crucial if we are going to right our sinking health care system while encouraging a healthier American populace. The purpose of this article is to present some of the immediate and long-term benefits of introducing integrative therapies to counter certain consequences of invasive treatments. Implementing such treatments can help defray the costs burdening the US medical care system.
A previous editorial discussed a systematic review of studies of complementary and alternative medicine (CAM) techniques compared with conventional therapies used for the same clinical conditions. This included a cost-effectiveness analysis. 1 Of these studies, 7 found that CAM therapy outcomes were significantly better than conventional methods but had lower or similar costs: 4 CAM therapy outcomes were similar to conventional outcomes but had lower or similar costs; 4 CAM therapy outcomes were better than conventional outcomes, but had higher costs; and 1 CAM therapy had similar outcomes but higher costs. Examples include the following: a relaxation tape used before colon surgery reduced the length of hospital stay by 1.6 days, at a cost savings of $3200 per patient, 2 whereas hypnosis as an adjunct to sedation for interventional radiology produced a savings of $338, along with reductions in both oversedation and undersedation. 3 Parenteral glutamine given to adult bone marrow transplant (BMT) patients in a 1994 study resulted in a reduced hospital stay of 1 full week with a savings of $21 095 per patient.
Whereas the above studies analyzed cost savings on a per-patient basis, it is also possible to extrapolate from such data to potential savings for society as a whole and for general medical concerns. For instance, a 6-month randomized trial of naturopathy for back pain in warehouse workers reported results in terms of quality-adjusted life years (QALYs). The workers assigned to naturopathy had 9.4 more days of what was labeled "perfect health"-a measure derived from QALYs-than workers assigned to conventional care. This symptom-free period resulted in reduced societal costs of $1212 per patient as well as reduced adjunctive care costs of $1096 per patient. From the employer's perspective, the days of "perfect health" translated to reduced absenteeism. The investigators calculated that the loss of productivity per day caused by absence was $175. The treatment cost to avoid an absent day was $154. Even if the employer were to pay the entire cost of treatment (which would probably not be the case), the return on investment for naturopathic treatment versus conventional care to avoid absenteeism would be 8%. 5 Another study assessed the use of a nutritional supplement containing chromium and biotin that had been found to improve glucose control (HbA1C) in type 2 diabetics in previous randomized trials. 6 Those studies demonstrated that the supplement, used in addition to oral hypoglycemic medications, resulted in better levels of HbA1C, especially in patients whose HbA1C was higher than 10%. The investigators calculated the average 3-year cost savings for improved control of diabetes that would be obtained by using the dietary supplement. For a patient with poor control (HbA1C more than 10%) but no hypertension or cardiovascular disease, the savings amounted to $1636. If a poorly controlled patient also had hypertension or cardiovascular disease, the savings totaled $5435. They further calculated that with the 16.3 million diabetic patients in the population at the time of the study (2005), the potential 3-year cost savings would range from $3.9 to $52.9 billion (depending on the numbers with and without the cited complications). If the 1.17 million new diabetic patients per year used the supplement continuously, a lifetime savings of $36 000 per patient would be realized, which is a total of $42 billion lifetime savings for the entire cohort of new patients.
When it comes to cancer, several studies of integrative therapies provide enough data to estimate potential savings. For this discussion, it is informative to extrapolate the possibility of savings by drawing on evidence from a range of investigations. For example, Montgomery et al 7 published research assessing the benefits of a single hypnosis session conducted with breast cancer patients just prior to breast biopsies. A cost-effectiveness analysis was part of the randomized trial of this 15-minute intervention. The cost savings attributable to the hypnosis procedure was $773, mostly from reduced medications and time spent in surgery. We projected what might be saved using this procedure to the total yearly population of breast cancer patients who would experience breast biopsies (Table 1 ). In the United States, an estimated 194 280 cases of breast cancer were diagnosed in 2009. 8 Based on these data, a conservative estimate for the number of biopsies that might be performed on the 92% of breast cancer patients who are likely candidates for this procedure (those with local and regional disease) is 178 738. This is a substantial underestimate: we are not including figures for the large numbers of patients whose biopsies revealed no cancer because this group was not included in the data set from which our cancer estimates are derived. Obviously, the savings would be much larger if this nonmalignant group that did undergo biopsies were included in biopsy numbers. The annual savings if only actual breast cancer patients undergoing biopsies received this hypnosis procedure would be $138 112 331. Of course, there is a cost to providing the preoperative procedure. Montgomery et al 7 suggest that on-premises institutional staff trained in light hypnosis would be able to deliver this relatively simple intervention. For a nurse who is paid an approximate $65 183 per year, 9 a half hour of time would amount to a $15.90 charge; this would be a reasonable estimate of the time commitment to perform and record the procedure in the medical chart. The costs in nurse time for this group of breast cancer biopsies would amount to $2 841 928. The net savings per year from this relatively 10 in a 1996 publication studied the effect of having adult BMT patients exercise on recumbent bicycles during their hospitalization (Integrative Cancer Therapies recently published a similar study on exercise in hospitalized leukemia patients).
11 Among other positive effects found in this randomized study, the authors noted that the exercise intervention shortened hospital stays by 1.6 days. We determined a possible number of BMTs needed in a year based on the estimated numbers of patients dying in 2009 from acute lymphocytic leukemia (1400), chronic lymphocytic leukemia (4390), multiple myeloma (10 850), and non-Hodgkins lymphoma (19 500; Table 2 ). 9 We used the numbers of deceased patients because it is not clear how many of the patients diagnosed at early stages would have received BMTs. We also lowered the numbers of deceased patients by 10% as a rough estimate of those who do not receive BMTs for various reasons. The total number of BMTs we thus projected was 32 382. We examined the effect of reducing hospital stay using only the cost of hospital rooms-not the multiple other medical, hospital, and ancillary expenses-because total daily costs of BMT hospitalization at the end of the hospital stay (when the shortened duration of stay would occur) were not available to us. A regular hospital room costs $1122 per day on average. 12 At a reduction of 1.6 days per patient, this amounts to a hospital room savings alone of $1795.20 per patient, or $57 954 442 for all the BMT patients in a year. Costs to administer this program would include purchase of exercise bikes and physical therapist time to train and supervise patients in the use of such equipment. There are approximately 130 registered BMT units in the United States. If each purchased only 2 recumbent exercise bikes costing $2400, 13 this would result in a nationwide cost of $312 000. If we assume each exercise bike lasts for 3 years, we could apportion an annual total cost of $104 000 for the placement of bikes in all the BMT units nationwide. A physical therapist is typically paid $94 000 per year. An hour of physical therapist time allocated to each BMT patient thus costs $45. The cost for an hour of physical therapist time for all BMT patients would be $1 452 735. Subtracting these expenses from the overall savings on hospital rooms would give a net savings of $56 397 707. Because the amount just represented reflects only the room expense but does not include the costs of services such as medications, nursing care, food, and other expenses of hospitalization, this projected savings is a considerable underestimate.
On the other hand, not all integrative interventions will be cost-effective even when they are therapeutically beneficial. For example, a common complication of chemotherapy is venous thromboembolism (VTE). A study by Belcaro et al 14 reports that in a randomized trial, chemotherapy patients who took 150 mg pycnogenol daily had a reduced number of VTEs relative to those without pycnogenol-4% in the pycnogenol group versus 19% in the control group. There are a number of estimates of percentages of chemotherapy patients who have VTEs; an average value derived from 7 references we located for the percentage of patients who experience VTEs is 6.145%. [15] [16] [17] [18] [19] [20] [21] A 2007 estimate for the cost of a primary VTE event is $10 804. 22 We estimated the number of chemotherapy patients per year as follows: 1 479 350 patients are diagnosed with cancer every year (Table 3) . Early-stage breast cancer patients (61% of the total, or 118 511) may not receive chemotherapy 9 nor do early-stage prostate cancer patients (192 280). The figures we use for cancer estimates exclude basal and squamous cell skin cancers, and patients with these do not receive chemotherapy nor do patients with most other nonepithelial skin cancers (5890). Excluding these populations, we arrive at a figure of 1 162 669 chemotherapy patients per year. If we use this estimate, the expected number of VTEs per year, at 6.145% of patients, is 70 922, and the total cost of caring for them is $766 250 028.
The amount to treat a cancer patient with pycnogenol during 6 months of chemotherapy is calculated based on a supplement that costs $69.98 for a 60-tablet bottle of 75 mg tablets and is $209.94 (Internet volume discount price as of March 2010). The cost to treat all cancer patients with pycnogenol would be $244 090 730. Based on the figures of Belcaro et al 14 (19% vs 4%), we would see a 79% reduction of VTEs or, with the addition of pycnogenol, only 14 929 annual VTE cases. The cost to treat these would be $161 295 631 (these VTE costs do not account for other financial consequences, such as loss of family income caused by the VTEs, which would appreciably alter the following figures). Adding the cost of the pycnogenol to the cost of treatment for the total costs of VTEs with pycnogenol prophylaxis, we find that the total would be $405 386 361. This is $360 863 668 less than the $766 250 028 calculated above without pycnogenol prophylaxis. This is a substantial savings, indeed.
However, the percentage of VTEs observed in the control group by Belcaro et al 14 (19%) is considerably higher than the other estimates we found for percentages of chemotherapy patients who experience VTEs. It might be more appropriate to use a much more conservative figure for the percentage reduction in VTEs than that generated by Belcaro et al in this small study. If we thus estimate only a 20% reduction in VTEs, the number of patients with VTEs would be 56 738. The cost to treat these VTEs is $613 000 023. The total cost of VTEs with pycnogenol prophylaxis in the 20% reduction scenario would be $857 090 753. This is $90 840 724 higher than the cost with no prophylaxis, that is, $766 250 028. Of course, this still does not take into account other family costs and losses, which certainly could shift the argument toward a favorable use of pycnogenol prophylaxis.
Whether it would be cost-effective to use pycnogenol as prophylaxis for chemotherapy-related VTEs is thus not resolved. Clinically, the reduction in VTEs from introducing this low-to no-risk supplement is clearly a good idea. The entire economic question, however, of VTE prophylaxis in cancer is, in fact, still an open one, especially for ambulatory versus hospitalized patients. 23 A conventional mode of thromboprophylaxis would be to use low-molecular-weight (LMW) heparins. Among the open questions of using LMW heparin are the possible benefits of such thromboprophylaxis for ambulatory patients, risk-benefit ratios, and the impact of anticoagulation on survival. Of course, as noted with pycnogenol, adding in other treatment-related costs of VTEs might change this cost-benefit analysis, as might adding in potential adverse effects of pycnogenol prophylaxis in cancer patients of which we are not yet aware. We would also need randomized trials of much better quality to determine whether the results of Belcaro et al 14 hold up in this setting. The costs and efficacy of pycnogenol would certainly need to be compared with that of LMW heparins. Also, the clinical value would need to be adequately compared with other supplement options.
Using a less expensive supplement might, in fact, substantially change the cost-benefit ratio of prophylaxis. We substituted vitamin E for pycnogenol in the above analysis (Table 4) . Vitamin E demonstrated VTE prophylaxis in the Women's Health Study, 24 especially in women with risk factors for VTE, although its effect was not determined specifically for chemotherapy patients. To provide insight on how changing only the cost of the supplement would affect our analysis, we used the same 2 levels of VTE risk reduction when adding a supplement as used above-79% as calculated from the Belcaro et al 14 data and 20% from our more conservative calculation. Confirming the actual amount of efficacy of vitamin E in VTE prophylaxis for chemotherapy patients would, of course, have to be determined by clinical trials. The cost for a 6-month supply of vitamin E at 600 IUs given every other day-the level used in the Women's Health Study-is 92% less per patient than pycnogenol. Using the data of Belcaro et al, we found a cost savings of $585 793 607 at a 79% reduction of VTEs. Using our more conservative modeling of a 20% reduction of VTEs, the cost savings is still a substantial $134 089 215.
Summary
What can we learn from this discussion? First, there are impressive clinical and economic benefits to be gained with the use of integrative interventions. The breast cancer hypnosis intervention is certainly among the easiest and quickest to implement on a large scale. Our cost-saving estimate is based on a medium-sized randomized trial (n = 200), and we excluded the large number of patients who receive breast biopsies but do not have cancer. We also excluded several other benefits of the hypnosis procedure: there were Total yearly savings significant reductions in duration and intensity of pain, nausea, fatigue, other physical discomforts, and emotional distress. These alone could argue for the widespread implementation of this procedure, but with the potential cost savings, it is extremely difficult to see why there has not already been a very large-scale randomized study conducted to examine the true feasibility of this intervention. The exercise intervention for patients hospitalized for BMTs is based on a smaller and older study; however, as the recent study by Battaglini et al 11 in Integrative Cancer Therapies shows, this is still an active area of research. This also represents an obvious intervention to evaluate in larger randomized studies. In addition to the value gained from reducing length of hospital stay, this exercise intervention offers long-term benefits if sessions encourage patients to sustain important health habits of fitness and good nutrition following their discharge.
It is my strong conviction, reinforced by considerable data, that a systematic integrative program could provide substantial help in shrinking the $1.3 trillion per year spent on preventable diseases in the United States 25 and an equally important reduction in cost and clinical burden for those combating existing illness. Far too often and far too insistently, we hear critics argue the unfeasibility of carrying an integrative model into clinical reality. Yet for 3 decades our center has found that it is possible to consistently provide a comprehensive integrative treatment experience for patients diagnosed with various cancers as well as other degenerative diseases and for those at high risk striving to improve their odds. Our experience demonstrates that there is substantial clinical and economic benefit by putting into practice whole systems care, where we provide comprehensive lifestyle strategies as opposed to 1 separate intervention at a time.
The estimates and extrapolations covered above suggest a broad spectrum of possibilities for improving patients' clinical well-being while lowering the economic challenges that are overwhelming our health care system. Our imperative is clear: We must methodically investigate the vast potential for cost savings by implementing integrative interventions. While addressing costs, these interventionssystematically combined with mainstream care-can also diminish adverse side effects, reduce treatment-related complications, and improve quality of life and, in fact, can be more humane and health promoting than an exclusive reliance on conventional treatments.
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